http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SU-1767429-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b18e6d9dbb813abfecb793a7f33a0936 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 1989-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1992-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8a1a8d988dc2435fbe2d26234fa52ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf2bfd25f45b604b49f9164c1839c8e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_481038f37d9f16bfd2f817c643a7a4fa |
| publicationDate | 1992-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | SU-1767429-A1 |
| titleOfInvention | Method of selecting optimum dose of acetylsalicylic acid in arterial thrombosis |
| abstract | Use: medicine, cardiologists, angiologists. Summary of the invention: in the blood sample of patients with aortic obliterans atherosclerosis and its branches, platelet aggregation activity is determined before and after the administration of acetylsalicylic acid, and the anti-aggregation activity of the vascular wall is additionally determined Cilicilic acid and with a decrease in the first indicator, compared with the initial value, and at a constant value of the second indicator relative to the initial value, this dose of the drug is considered the optimal therapeutic dose Oh. 1 tab. |
| priorityDate | 1989-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.